Impact of elexacaftor-tezacaftor-ivacaftor in lung transplantation for cystic fibrosis in the United States by Tahuanty A. Pena, MD, MS, Brittany Wright, PharmD, Kalpaj R. Parekh, MBBS, Julia Kleney-Tait, MD, PhD

Subjects: Get full text

Prevalence and characteristics of gastrointestinal disorders, medication use, and diagnostic interventions in pediatric patients with cystic fibrosis: a nested case–control analysi... by Carolena Trocchia, Carolena Trocchia, Maua Mosha, Bailey Hamner, Neil Goldenberg, Racha Khalaf

Subjects: “…elexacaftor/tezacaftor/ivacaftor (ETI)…”
Get full text

The complexities of elexacaftor/tezacaftor/ivacaftor therapeutic drug monitoring in a person with cystic fibrosis and Mycobacterium abscessus pulmonary disease by Claire Y Mou, Daniel J Henderson, Angela G Matson, Karen M Herd, David W Reid, Timothy Riddles, Ellie Johnson, Brett McWhinney, Rebecca Swenson, Andrew Burke, Ieuan E S Evans

Subjects: “…elexacaftor/tezacaftor/ivacaftor…”
Get full text

Non-classical pulmonary exacerbation in cystic fibrosis revealing ALK-Translocated lung cancer: A case report by Mohamad Hadhud, Johnathan Arnon, Anat Hershko-Moshe, Adi Hollander, Noa Hurvitz-Lehmann, Assaf Potruch, Henny Azmanov, Rottem Kuint, Nurith Hiller, Elie Picard, Naama Sebbag-Sznajder, Shira Leebhoff, Michael Wilschanski, Myriam Grunewald, Liron Birimberg-Schwartz, Malena Cohen-Cymberknoh

Subjects: “…Elexacaftor/tezacaftor/ivacaftor…”
Get full text